Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Pharvaris ( (PHVS) ) is now available.
On November 12, 2025, Pharvaris reported its financial results for the third quarter of 2025 and provided updates on its business operations. The company highlighted the progress of its pivotal Phase 3 studies, including RAPIDe-3 and CHAPTER-3, which are evaluating deucrictibant for the treatment and prevention of HAE attacks. Pharvaris also initiated the CREAATE study for AAE-C1INH attacks. The company maintains a strong financial position with €329 million in cash and cash equivalents, and it successfully closed a $201 million public offering to extend its cash runway into the first half of 2027. These developments underscore Pharvaris’ commitment to advancing its pipeline and enhancing its market positioning in the treatment of bradykinin-mediated diseases.
The most recent analyst rating on (PHVS) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Pharvaris stock, see the PHVS Stock Forecast page.
Spark’s Take on PHVS Stock
According to Spark, TipRanks’ AI Analyst, PHVS is a Neutral.
Pharvaris exhibits significant financial difficulties, with no revenue and ongoing losses, resulting in a low financial performance score. Despite some technical momentum, the valuation is poor due to negative earnings. The stock’s overall score is affected by these financial and valuation challenges, despite its technical strength.
To see Spark’s full report on PHVS stock, click here.
More about Pharvaris
Pharvaris is a late-stage biopharmaceutical company focused on developing novel, oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The company aims to provide injectable-like efficacy and placebo-like tolerability with the convenience of oral therapies.
Average Trading Volume: 195,603
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.45B
Learn more about PHVS stock on TipRanks’ Stock Analysis page.